| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11894-006-0039-Z |
| P698 | PubMed publication ID | 17105688 |
| P50 | author | Richard N. Fedorak | Q43531400 |
| P2093 | author name string | Julia B Ewaschuk | |
| Isaac Soo | |||
| Karen Madsen | |||
| Qassim Z Tejpar | |||
| P2860 | cites work | Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice | Q24523182 |
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
| Lactobacillus GG in inducing and maintaining remission of Crohn's disease | Q24806098 | ||
| Saccharomyces boulardii in maintenance treatment of Crohn's disease | Q28144634 | ||
| Treatment of ulcerative colitis using fecal bacteriotherapy | Q28179819 | ||
| A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 | ||
| Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial | Q28213579 | ||
| A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result | Q28260707 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells | Q32109047 | ||
| Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). | Q33212468 | ||
| Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells | Q33554139 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Double blind, placebo controlled trial of metronidazole in Crohn's disease | Q34394436 | ||
| Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial | Q34410821 | ||
| Probiotics in man and animals | Q34505006 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis | Q34530929 | ||
| A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease | Q34560319 | ||
| Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. | Q34566470 | ||
| Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
| Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC) | Q35595770 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial | Q35707325 | ||
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
| Probiotics and the management of inflammatory bowel disease. | Q35854517 | ||
| Towards understanding molecular modes of probiotic action | Q36410699 | ||
| Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats | Q39769547 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro | Q42282244 | ||
| Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. | Q42674728 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Mucosal flora in inflammatory bowel disease | Q43503928 | ||
| A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis | Q43719249 | ||
| A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis | Q43807182 | ||
| Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis | Q43867015 | ||
| Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. | Q44629149 | ||
| Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis | Q45166043 | ||
| Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis | Q45273376 | ||
| Oral tobramycin in ulcerative colitis: effect on maintenance of remission. | Q52873006 | ||
| Open label trial of oral clarithromycin in active Crohn's disease. | Q53910434 | ||
| An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. | Q54727809 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Rifaximin for active ulcerative colitis | Q59541334 | ||
| Is Lactobacillus GG Helpful in Children With Crohn’s Disease? Results of a Preliminary, Open-Label Study | Q63285887 | ||
| Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) | Q70823350 | ||
| Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection | Q72281835 | ||
| Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis | Q72688420 | ||
| Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora | Q73092300 | ||
| Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? | Q74126152 | ||
| A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) | Q74623807 | ||
| Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study | Q77494204 | ||
| Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis | Q83333118 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| inflammatory bowel diseases | Q917447 | ||
| probiotics | Q1816730 | ||
| P304 | page(s) | 486-498 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Current gastroenterology reports | Q26842032 |
| P1476 | title | The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease | |
| P478 | volume | 8 |
| Q37724675 | Combined probiotic bacteria promotes intestinal epithelial barrier function in interleukin-10-gene-deficient mice |
| Q35069242 | Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients |
| Q42206416 | Fc gamma receptor signaling in mast cells links microbial stimulation to mucosal immune inflammation in the intestine |
| Q28238138 | Gut bacteria in health and disease |
| Q37082773 | Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease |
| Q29618086 | Intestinal mucosal barrier function in health and disease |
| Q37123770 | Microbial host interactions in IBD: implications for pathogenesis and therapy |
| Q27342619 | Oligomannan Prebiotic Attenuates Immunological, Clinical and Behavioral Symptoms in Mouse Model of Inflammatory Bowel Disease |
| Q37962875 | Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults |
| Q41778200 | Probiotic Therapies for IBD. |
| Q82416873 | Probiotics in Gastrointestinal Disorders |
| Q33438518 | Probiotics in the management of colonic disorders |
| Q42737532 | Protective effect of the methanolic extract of malva parviflora l. leaves on acetic acid-induced ulcerative colitis in rats |
| Q45573898 | Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. |
| Q34407175 | Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? |
| Q24651518 | Skin microbiota: a source of disease or defence? |
| Q36184706 | The effect of bifid triple viable on immune function of patients with ulcerative colitis |
| Q29614801 | The human microbiome: at the interface of health and disease |
| Q38068230 | The new prophylactic strategy for colon cancer in inflammatory bowel disease by modulating microbiota |
| Q37263006 | Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory |
Search more.